

Highlights of This Issue 2655

SPECIAL FEATURES

CCR 20th Anniversary Commentary

- 2657** CCR 20th Anniversary Commentary: From Regulatory T Cells to Checkpoint Monoclonal Antibodies—Immuno-oncology Advances Clinical Cancer Research
Dominik Wolf and Anna Maria Wolf

CCR Translations

- 2660** CD38-Targeted Immunochemotherapy in Refractory Multiple Myeloma: A New Horizon
Jacob P. Laubach and Paul G. Richardson
See related article, p. 2802
- 2663** "Vertical" Inhibition of HER2 Yields Horizontal Gains in the Clinic
George W. Sledge and Mark D. Pegram
See related article, p. 2737

CCR Perspectives in Drug Approval

- 2666** FDA Approval: Belinostat for the Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma
Hyon-Zu Lee, Virginia E. Kwitkowski, Pedro L. Del Valle, M. Stacey Ricci, Haleh Saber, Bahru A. Habtemariam, Julie Bullock, Erik Bloomquist, Yuan Li Shen, Xiao-Hong Chen, Janice Brown, Nitin Mehrotra, Sarah Dorff, Rosane Charlab, Robert C. Kane, Edvardas Kaminskas, Robert Justice, Ann T. Farrell, and Richard Pazdur

Molecular Pathways

- 2671** Molecular Pathways: Leveraging the BCL-2 Interactome to Kill Cancer Cells—Mitochondrial Outer Membrane Permeabilization and Beyond
Hetal Brahmabhatt, Sina Oppermann, Elizabeth J. Osterlund, Brian Leber, and David W. Andrews

Reviews

- 2677** Management of Cutaneous and Extracutaneous Side Effects of Smoothed Inhibitor Therapy for Advanced Basal Cell Carcinoma
Shalini V. Mohan and Anne Lynn S. Chang
- 2684** Targeting FGFR Signaling in Cancer
 Mehdi Touat, Ecaterina Ileana, Sophie Postel-Vinay, Fabrice André, and Jean-Charles Soria


CANCER THERAPY: CLINICAL

- 2695** A Phase I First-in-Human Study of Enoticumab (REGN421), a Fully Human Delta-like Ligand 4 (Dll4) Monoclonal Antibody in Patients with Advanced Solid Tumors
Elena Gabriela Chiorean, Patricia LoRusso, Robert Matthew Strother, Jennifer R. Diamond, Anne Younger, Wells A. Messersmith, Lieve Adriaens, Liming Liu, Richard J. Kao, Albert Thomas DiCioccio, Ana Kostic, Russell Leek, Adrian Harris, and Antonio Jimeno
- 2704** A Phase I/II Study of the mTOR Inhibitor Everolimus in Combination with HyperCVAD Chemotherapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia
Naval Daver, Yanis Boumber, Hagop Kantarjian, Farhad Ravandi, Jorge Cortes, Michael E. Rytting, Jitesh D. Kawedia, Jordan Basnett, Kirk S. Culotta, Zhihong Zeng, Hongbo Lu, Mary Ann Richie, Rebecca Garris, Lianchun Xiao, Wenbin Liu, Keith A. Baggerly, Elias Jabbour, Susan O'Brien, Jan Burger, Linda J. Bendall, Deborah Thomas, and Marina Konopleva
- 2715** Phase I Study of Vorinostat as a Radiation Sensitizer with ¹³¹I-Metaiodobenzylguanidine (¹³¹I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma
Steven G. DuBois, Susan Groshen, Julie R. Park, Daphne A. Haas-Kogan, Xiaodong Yang, Ethan Geier, Eugene Chen, Kathy Giacomini, Brian Weiss, Susan L. Cohn, M. Meaghan Granger, Gregory A. Yanik, Randall Hawkins, Jesse Courtier, Hollie Jackson, Fariba Goodarzi, Hiroyuki Shimada, Scarlett Czamecki, Denice Tsao-Wei, Judith G. Villablanca, Araz Marachelian, and Katherine K. Matthey

Table of Contents

2722 TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer

Andres Forero-Torres, Katherine E. Varley, Vandana G. Abramson, Yufeng Li, Christos Vakilavass, Nancy U. Lin, Minetta C. Liu, Hope S. Rugo, Rita Nanda, Anna M. Storniolo, Tiffany A. Traina, Sujata Patil, Catherine H. Van Poznak, Julie R. Nangia, William J. Irvin Jr, Helen Krontiras, Jennifer F. De Los Santos, Paul Haluska, William Grizzle, Richard M. Myers, and Antonio C. Wolff on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
See related article, p. 2771

2730  A Phase I Dose-Escalation Study of Antibody BI-505 in Relapsed/Refractory Multiple Myeloma

Markus Hansson, Peter Gimsing, Ashraf Badros, Titti Martinsson Niskanen, Hareth Nahi, Fritz Offner, Morten Salomo, Elisabeth Sonesson, Morten Mau-Sorensen, Yvonne Stenberg, Annika Sundberg, Ingrid Teige, Jan Van Droogenbroeck, Stina Wichert, Maurizio Zangari, Björn Frendeus, Magnus Korsgren, Martine Poelman, and Guido Tricot

2737 Phase I Study to Assess the Combination of Afatinib with Trastuzumab in Patients with Advanced or Metastatic HER2-Positive Breast Cancer

Alistair Ring, Duncan Wheatley, Helen Hatcher, Robert Laing, Ruth Plummer, Martina Uttenreuther-Fischer, Graham Temple, Katy Pelling, and David Schnell
See related commentary, p. 2663

2745 Progression-Free and Overall Survival in ALK-Positive NSCLC Patients Treated with Sequential Crizotinib and Ceritinib

Justin F. Gainor, Daniel S.W. Tan, Tomasso De Pas, Benjamin J. Solomon, Aziah Ahmad, Chiara Lazzari, Filippo de Marinis, Gianluca Spitaleri, Katherine Schultz, Luc Friboulet, Beow Y. Yeap, Jeffrey A. Engelman, and Alice T. Shaw

PERSONALIZED MEDICINE AND IMAGING

2753  CD44 Isoform Status Predicts Response to Treatment with Anti-CD44 Antibody in Cancer Patients

Fabian Birzele, Edgar Voss, Adam Nopora, Konrad Honold, Florian Heil, Sabine Lohmann, Henk Verheul, Christophe Le Tourneau, Jean-Pierre Delord, Carla van Herpen, Devalingam Mahalingam, Andrew L. Coveler, Valerie Meresse, Stefan Weigand, Valeria Runza, and Michael Cannarile

2763 Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer

Mitch Dowsett, Ivana Sestak, Richard Buus, Elena Lopez-Knowles, Elizabeth Mallon, Anthony Howell, John F. Forbes, Aman Buzdar, and Jack Cuzick

2771 Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019

Costanza Paoletti, Yufeng Li, Maria C. Muñiz, Kelley M. Kidwell, Kimberly Aung, Dafydd G. Thomas, Martha E. Brown, Vandana G. Abramson, William J. Irvin Jr, Nancy U. Lin, Minetta C. Liu, Rita Nanda, Julie R. Nangia, Anna M. Storniolo, Tiffany A. Traina, Christos Vakilavass, Catherine H. Van Poznak, Antonio C. Wolff, Andres Forero-Torres, and Daniel F. Hayes on behalf of the Translational Breast Cancer Research Consortium (TBCRC)
See related article, p. 2722

CANCER THERAPY: PRECLINICAL

2780 Methionine Deprivation Induces a Targetable Vulnerability in Triple-Negative Breast Cancer Cells by Enhancing TRAIL Receptor-2 Expression
Elena Strelakova, Dmitry Malin, David M. Good, and Vincent L. Cryns

2792 Radiation Enhancement of Head and Neck Squamous Cell Carcinoma by the Dual PI3K/mTOR Inhibitor PF-05212384

Andrew J. Leiker, William DeGraff, Rajani Choudhuri, Anastasia L. Sowers, Angela Thetford, John A. Cook, Carter Van Waes, and James B. Mitchell

2802 Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

Inger S. Nijhof, Richard W.J. Groen, Willy A. Noort, Berris van Kessel, Regina de Jong-Korlaar, Joost Bakker, Jeroen J.L. van Bueren, Paul W.H.I. Parren, Henk M. Lokhorst, Niels W.C.J. van de Donk, Anton C.M. Martens, and Tuna Mutis
See related commentary, p. 2660

2811  The MET Inhibitor AZD6094 (Savolitinib, HMPL-504) Induces Regression in Papillary Renal Cell Carcinoma Patient-Derived Xenograft Models

Alwin G. Schuller, Evan R. Barry, Rhys D.O. Jones, Ryan E. Henry, Melanie M. Frigault, Garry Beran, David Linsenmayer, Maureen Hattersley, Aaron Smith, Joanne Wilson, Stefano Cairo, Olivier Déas, Delphine Nicolle, Ammar Adam, Michael Zinda, Corinne Reimer, Stephen E. Fawell, Edwin A. Clark, and Celina M. D'Cruz

Table of Contents

BIOLOGY OF HUMAN TUMORS

- 2820** The Use of Transcriptional Profiling to Improve Personalized Diagnosis and Management of Cutaneous T-cell Lymphoma (CTCL)
Ivan V. Litvinov, Elena Netchiporouk, Brendan Cordeiro, Marc-André Doré, Linda Moreau, Kevin Pehr, Martin Gilbert, Youwen Zhou, Denis Sasseville, and Thomas S. Kupper
- 2830** Prognostic Significance of Tryptophan Catabolism in Adult T-cell Leukemia/Lymphoma
Ayako Masaki, Takashi Ishida, Yasuhiro Maeda, Susumu Suzuki, Asahi Ito, Hisashi Takino, Hiroka Ogura, Haruhito Totani, Takashi Yoshida, Shiori Kinoshita, Tomoko Narita, Masaki Ri, Shigeru Kusumoto, Atsushi Inagaki, Hirokazu Komatsu, Akio Niimi, Ryuzo Ueda, Atae Utsunomiya, Hiroshi Inagaki, and Shinsuke Iida
- 2840** The Ovarian Cancer Chemokine Landscape Is Conducive to Homing of Vaccine-Primed and CD3/CD28–Costimulated T Cells Prepared for Adoptive Therapy
Emese Zsiros, Priyanka Duttagupta, Denarda Dangaj, Hongzhe Li, Renee Frank, Thomas Garrabrant, Ian S. Hagemann, Bruce L. Levine, Carl H. June, Lin Zhang, Ena Wang, Francesco M. Marincola, Davide Bedognetti, Daniel J. Powell Jr, Janos Tanyi, Michael D. Feldman, Lana E. Kandalaf, and George Coukos
- 2851** Immunohistochemical Loss of LKB1 Is a Biomarker for More Aggressive Biology in *KRAS*-Mutant Lung Adenocarcinoma
Antonio Calles, Lynette M. Sholl, Scott J. Rodig, Ashley K. Pelton, Jason L. Hornick, Mohit Butaney, Christine Lydon, Suzanne E. Dahlberg, Geoffrey R. Oxnard, David M. Jackman, and Pasi A. Jänne
- 2861** HPV Serum Antibodies as Predictors of Survival and Disease Progression in Patients with HPV-Positive Squamous Cell Carcinoma of the Oropharynx
Kristina R. Dahlstrom, Karen S. Anderson, Julia N. Cheng, Diego Chowell, Guojun Li, Marshall Posner, and Erich M. Sturgis
- 2870** SIRT1/PGC1 α -Dependent Increase in Oxidative Phosphorylation Supports Chemotherapy Resistance of Colon Cancer
Thomas T. Vellinga, Tijana Borovski, Vincent C.J. de Boer, Szabolcs Fatrai, Susanne van Schelven, Kari Trumpi, Andre Verheem, Nikol Snoeren, Benjamin L. Emmink, Jan Koster, Inne H.M. Borel Rinkes, and Onno Kranenburg


 AC icon indicates Author Choice

 CME icon indicates that this article is available for continuing medical education credit at <http://cme.aacrjournals.org>

For more information please visit www.aacrjournals.org

ABOUT THE COVER

The cover shows head and neck squamous cell carcinoma (UMSCC1) xenograft tissue sections harvested after treatment with the dual PI3k/mTOR inhibitor PF-05212384. Immunohistochemical staining demonstrates a significant reduction in phospho-S6 fluorescence (green) with intravenous PF-05212384 treatment. For details, see the article by Leiker and colleagues on page 2792 of this issue.



Clinical Cancer Research

21 (12)

Clin Cancer Res 2015;21:2655-2879.

Updated version Access the most recent version of this article at:
<http://clincancerres.aacrjournals.org/content/21/12>

E-mail alerts [Sign up to receive free email-alerts](#) related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/21/12>.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.